Hepatitis B Surface Antibody Test

Hepatitis B is one of the most common serious infections in the world, and most people who are vulnerable to it have no idea. You may have been vaccinated as a child, or you may have been exposed at some point and cleared the virus on your own. Either way, the question that matters right now is simple: does your body actually have the antibodies it needs to keep you protected? Anti-HBs (hepatitis B surface antibody) is the answer to that question.

This antibody is produced by a type of white blood cell called a B cell after your immune system encounters the hepatitis B surface antigen, either through vaccination or natural infection. A positive result means your immune system has learned to recognize and neutralize the virus. A negative result means you are unprotected, and if you are exposed, you could develop an infection that ranges from a short illness to a lifelong chronic disease with serious liver consequences.

What This Antibody Tells You

Anti-HBs is not a test for active infection. It is the opposite: it tells you whether your body has successfully mounted a defense against the virus. When your level is at or above 10 mIU/mL, you are considered immune. When it is below that threshold, you are susceptible to hepatitis B infection, regardless of whether you were vaccinated in the past.

There are two routes to developing this antibody. The first is vaccination: if you received the hepatitis B vaccine series and responded to it, your body should produce anti-HBs without any other hepatitis B markers. The second is natural infection followed by recovery: about 80% of people who clear a hepatitis B infection develop detectable anti-HBs. In this case, another marker called anti-HBc (hepatitis B core antibody) will also be present, confirming that the immunity came from a real infection rather than a vaccine.

Why Your Vaccination May Not Have Worked

Many people assume that if they received the hepatitis B vaccine, they are protected for life. This is not always true. Vaccine response rates vary dramatically depending on age and health status. More than 95% of healthy young adults develop protective antibody levels after completing the vaccine series. But for adults over 60, that number drops to 60 to 75%. For people on dialysis, it can be as low as 48 to 60% even with double-dose vaccination.

Smoking increases your risk of not responding to the vaccine by about 53%. Obesity (BMI of 25 or higher) raises that risk by about 56%. Diabetes, chronic kidney disease, and chronic liver disease also impair vaccine response. A meta-analysis of over 21,000 adults confirmed that smoking and obesity are among the strongest predictors of vaccine nonresponse. If you have any of these risk factors, the only way to know your actual immunity status is to test.

Liver Cancer and Chronic Liver Disease Risk

The consequences of lacking anti-HBs protection extend well beyond the acute infection itself. Without immunity, an exposure to hepatitis B can progress to chronic infection, defined as having the hepatitis B surface antigen (HBsAg) persist in your blood for more than six months. Chronic infection substantially raises the risk of cirrhosis (severe liver scarring) and liver cancer.

A large prospective study from China following nearly 476,000 adults for approximately ten years found that those who were HBsAg-positive (chronically infected and therefore lacking effective anti-HBs protection) had a roughly doubled risk of dying from any cause and a nearly 14-fold higher risk of dying from liver cancer. The same study found elevated risks of bleeding in the brain and heart disease caused by blocked arteries. A Japanese study of nearly 7,000 men followed for an average of 8.5 years found that anti-HBs-positive individuals had no increased risk of dying from liver cancer or other liver diseases, confirming the protective value of this antibody.

Protection Beyond Liver Disease

Emerging evidence suggests that anti-HBs positivity may carry protective associations beyond hepatitis B itself. A study of cancer survivors from the U.S. National Health and Nutrition Examination Survey (NHANES) found that those with anti-HBs had a 39% lower risk of death compared to those without it. This protective association was validated in a separate cohort of gastric cancer patients, where anti-HBs positivity was associated with a 23% reduction in mortality risk.

In hemodialysis patients, failing to respond to the hepatitis B vaccine (and therefore lacking anti-HBs) was independently associated with higher all-cause mortality over a six-year follow-up. These findings suggest that anti-HBs status may serve as a broader marker of immune competence, though more research is needed to confirm whether the antibody itself drives these benefits or simply reflects a healthier immune system.

Reactivation Risk for People with Past Infection

If you had hepatitis B in the past and recovered, the virus can hide at very low levels in liver cells even after your blood tests look normal. This dormant virus can reactivate if your immune system is suppressed by chemotherapy, organ transplant medications, or biologic drugs like rituximab. Anti-HBs provides a layer of defense against this reactivation.

A meta-analysis of 20 studies involving over 1,600 patients with past hepatitis B who received chemotherapy for blood cancers found that those with detectable anti-HBs had roughly a 79% lower risk of viral reactivation compared to those without it. The reactivation rate was 5% in patients with anti-HBs versus 14% in those without. For patients receiving rituximab specifically, anti-HBs reduced reactivation odds by about 81%. Knowing your anti-HBs level before starting immunosuppressive treatment is essential for deciding whether you need antiviral prophylaxis.

Reference Ranges

Different commercial assays can produce different numerical results for the same sample. A comparison of nine anti-HBs assays found a mean variation of 47.1% between measurement systems, with some assays producing results more than twice as high as others. For this reason, you should always compare results from the same lab when tracking your level over time.

These tiers are drawn from published guidelines. The 10 mIU/mL threshold is consistent across all major guideline bodies. The 100 mIU/mL benchmark is used specifically in HIV guidelines and for assessing reactivation risk before immunosuppressive therapy. Your lab may use slightly different assays and cutpoints, so compare your results within the same lab over time for the most meaningful trend.

Tracking Your Trend

Anti-HBs levels naturally decline over time after vaccination or infection. How fast they fall depends on how high they peaked. People whose levels exceeded 10,000 IU/L after vaccination maintained protective levels for at least six years, while those who peaked between 10 and 100 IU/L lost protection within four years. After four years, more than a third of immunocompetent adults who were vaccinated have levels below the protective threshold.

For most healthy adults who initially responded to the vaccine, immune memory (the ability of your B cells to rapidly produce new antibodies when re-exposed to the virus) persists for 30 years or more, even when circulating antibody levels drop below 10 mIU/mL. A booster dose can confirm this memory: if your level rebounds above 10 mIU/mL after a single dose, your immune system still remembers the virus. For people on dialysis, antibody decay is faster, with studies showing a steep logarithmic decline that necessitates monitoring every 6 to 12 months.

If you are immunocompetent and your initial vaccine response was confirmed, a single check may be sufficient unless you face new risk factors. If you are immunocompromised, on dialysis, or about to start immunosuppressive therapy, you should check your level now and retest at least annually. If you are making changes to your vaccination status, retest one to two months after completing your series to confirm response.

When Results Can Be Misleading

The biggest source of measurement error is assay variation. With a 47.1% average coefficient of variation between different commercial platforms, switching labs between tests can produce meaningfully different numbers even when your actual antibody level has not changed. Some enzyme-based assays tend to read lower than automated systems. If your result is near the 10 mIU/mL cutoff, the assay used could determine whether you are classified as protected or unprotected.

There is a natural period during recovery from acute hepatitis B infection, lasting one to six months, when the surface antigen (HBsAg) has disappeared but anti-HBs has not yet appeared. During this window, both markers may be negative, and the only detectable sign of recent infection is a different marker called IgM anti-HBc. If you are tested during this window, you could appear to have no immunity and no infection, which would be misleading.

Certain medications suppress the immune system enough to reduce circulating anti-HBs. B-cell depleting drugs like rituximab carry the highest risk: one study found that 18% of patients with pre-treatment anti-HBs below 100 mIU/mL lost their antibodies entirely during treatment, while none of those starting above 100 mIU/mL did. High-dose corticosteroids (more than 20 mg prednisone equivalent daily for four or more weeks) can cause the hepatitis B surface antigen to reappear in the blood (a process called seroreversion) in people with past exposure. These are genuine immune effects rather than assay artifacts, but they can complicate interpretation if you are being monitored while on these drugs.